Daewoong Pharmaceutical announced Tuesday that it has filed for a domestic patent for a new obesity drug that suppresses ...

Boston Scientific Corp.’s OPTION study demonstrated left atrial appendage closure with the Watchman Flx device reduced risk of stroke compared to management with direct oral anticoagulants or warfarin ...

Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new British research shows.

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers ...

Novo Nordisk, the biggest seller in the GLP-1 market, announced earlier this month it was seeking regulatory approval for ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Lower Manhattan-based Metsera is one of the latest drug startups to throw its hat into the ring with the pharma giants ...

GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

Waystar upped its 2024 outlook and now expects total revenue to range between $926 million and $934 million, compared to ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...